Olmesartan Medoxomil (40mg) + Amlodipine (5mg) + Hydrochlorothiazide (12.5mg) (Medical Monograph)

Overview

A triple-drug, fixed-dose combination (FDC) antihypertensive medication containing an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. It is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on any two of the following antihypertensive classes: ARBs, CCBs, and thiazide diuretics. This combination provides synergistic blood pressure lowering through complementary mechanisms, often allowing for lower doses of individual components and improved adherence.

This combination exerts a multi-pronged antihypertensive effect. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting its vasoconstrictive and aldosterone-secreting effects. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.